Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 12:53 AM
Ignite Modification Date:
2025-12-25 @ 12:53 AM
NCT ID:
NCT00006267
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed recurrent or metastatic ovarian epithelial or primary peritoneal cancer
* Measurable disease
* Ascites and pleural effusions are not considered measurable
* Sonography allowed if bidimensionally measurable
* Must not be eligible for higher priority GOG protocol
PATIENT CHARACTERISTICS:
Age:
* Not specified
Performance status:
* GOG 0-2
Life expectancy:
* Not specified
Hematopoietic:
* WBC at least 3,000/mm\^3
* Platelet count at least 100,000/mm\^3
* Granulocyte count at least 1,500/mm\^3
Hepatic:
* Bilirubin no greater than 1.5 times upper limit of normal (ULN)
* SGOT and alkaline phosphatase no greater than 3 times ULN
Renal:
* Creatinine no greater than 2.0 mg/dL
Other:
* No other prior or concurrent invasive malignancy in the past 5 years except nonmelanoma skin cancer
* No active infection
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* At least but no more than 2 prior chemotherapy regimens containing carboplatin, cisplatin, or another organoplatinum compound combined with paclitaxel
* Second line therapy may include any agents except topoisomerase I inhibitors (i.e., topotecan)
* No prior nitrocamptothecin or topoisomerase I inhibitors
* At least 3 weeks since prior chemotherapy and recovered
Endocrine therapy:
* Not specified
Radiotherapy:
* At least 3 weeks since prior radiotherapy and recovered
Surgery:
* At least 3 weeks since prior surgery and recovered
Other:
* No prior cancer therapy that contraindicates this study
Healthy Volunteers:
False
Sex:
FEMALE
Study:
NCT00006267
Study Brief:
Protocol Section:
NCT00006267